Location：
Home >
中国多肽化妆品市场进入高速增长期

中国多肽化妆品市场进入高速增长期

2025-11-25 09:26
19

中国多肽化妆品市场进入高速增长期


中国多肽化妆品市场虽起步较晚，但凭借独特的市场活力和快速迭代的本土创新，已成为全球美妆行业增长最快的细分领域之一。尽管国际品牌在肽类成分研发上拥有先发优势，但受限于市场战略错位和本土化不足，其技术积累并未转化为市场主导力。相反，以韩束为代表的国产品牌通过精准定位和技术突破，成功占据消费者心智，推动市场呈现“国货主导、多极竞争”的格局。截至2025年，该市场仍处于高速增长的“发力前期”，技术红利与消费升

News
Prev Breaking News: Guizhou Utide Biotechnology’s Tirzepatide and Retatrutide Successfully Pass U.S. Drug Master File (DMF) Filing for Peptide Active Pharmaceutical Ingredients!

Phase 3 Shock: Novo Nordisk’s CagriSema Loses to Eli Lilly’s Tirzepatide

2026-02-28
I. Market Insight: The New Standard of EfficacyOn February 23, 2026, Novo Nordisk released the REDEFINE 4 Phase 3 results—a head-to-head trial to challenge Eli Lilly’s GLP-1 market dominance. Data ...
News

Pfizer-Xianweida Collaboration Ignites GLP-1 API Boom: Guizhou Utide’s Customer Cases Reveal Its Core Strength

2026-02-28
       Recently, a major collaboration between Pfizer and Xianweida has become a hot topic in the global pharmaceutical industry — the two parties have joined hands to promote the commercializatio...
News

The Hidden War Behind the Pharmaceutical King's Succession: How a $36.5 Billion Order Tests the Global Supply Chain

2026-02-28
Ⅰ. A historic shiftIn 2025, the global pharmaceutical industrysaw a historic shift: Eli Lilly’s tirzepatide narrowlydethroned Novo Nordisk’s semaglutide as the new"King of Pharmaceuticals" with $36...
News

Eli Lilly’s GLP-1 Therapy Breakthrough:Global Peptide API Demand Surges, Highlighting UTIDE’s Guizhou Manufacturing& HK Commercial Capabilities

2026-02-28
1. Hot Spot Cut-In: Eli Lilly’s Trial Boosts GLP-1 Peptide API DemandOn January 8, 2026, Eli Lilly and Company announced positive top-line results from its Phase IIIb TOGETHER-PsA study, evaluating...
News

Starbucks Menu Overhaul: Viral High-Protein, Small-Portion Options Reveal Hidden Shifts in GLP-1 Supply Chain

2026-02-28
Seattle, USA — A pivotal shift from café menus to core manufacturing is underway, as global coffee giant Starbucks takes the lead in adapting to GLP-1-driven dietary changes by launching and expan...
News